Pre-Tax Income: Company's earnings or loss before taxes on income have been accounted for.
Lyell Immunopharma, Inc. (LYEL) had Pre-Tax Income of $-44.76M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
$0.00M |
|
$-44.76M |
|
-- |
|
$0.00M |
|
$47.34M |
|
$-47.34M |
|
$2.58M |
|
|
Pre-Tax Income |
$-44.76M |
$-44.76M |
|
$-44.76M |
|
$-44.76M |
|
$-44.76M |
|
$-44.76M |
|
$-47.34M |
|
$-45.94M |
|
23.36M |
|
23.36M |
|
$-1.92 |
|
$-1.92 |
|
| Balance Sheet Financials | |
$213.54M |
|
$30.51M |
|
$97.61M |
|
$311.15M |
|
$39.87M |
|
-- |
|
$37.47M |
|
$77.34M |
|
$233.81M |
|
$233.81M |
|
$233.81M |
|
23.40M |
|
| Cash Flow Statement Financials | |
$-72.43M |
|
$32.99M |
|
$52.24M |
|
$61.77M |
|
$74.57M |
|
$12.81M |
|
$8.83M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
5.36 |
|
-- |
|
-- |
|
-- |
|
-- |
|
100.00% |
|
-1183425.00% |
|
-1183425.00% |
|
-- |
|
-1118875.00% |
|
-1118875.00% |
|
$-72.77M |
|
-- |
|
-- |
|
-- |
|
0.00 |
|
-- |
|
-- |
|
-- |
|
-19.14% |
|
-19.14% |
|
-14.38% |
|
-19.14% |
|
$9.99 |
|
$-3.11 |
|
$-3.10 |
|